Prostate Cancer

During a Targeted Oncology case-based roundtable event, Susan Slovin, MD, discussed the next line of therapy for a patient with progressed metastatic castration-resistant prostate cancer with new liver metastasis.

John E. Sylvester, MD, a radiation oncologist with GenesisCare, reviews the importance of treating prostate cancer at the earliest stage possible.

In an interview with Targeted Oncology, Chad Tang, MD, The University of Texas MD Anderson Cancer Center, discussed background and implication of findings from the EXTEND trial.

In patients with PSMA-positive metastatic castration-resistant prostate cancer, the PSMA-directed therapy with 177Lu-PSMA-617, led to significant improvement in radiographic progression-free survival.

Fred Saad, MD, FRSC, discusses the findings of a biomarker analysis of the PROpel trial in patients with metastatic castration-resistant prostate cancer.

During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants the use of cabazitaxel in a patient with metastatic castration-resistant prostate cancer who did not tolerate docetaxel.

During a Targeted Oncology case-based roundtable event, Yousef Zakharia, MD, discussed new data supporting later-line options for patients with metastatic castration-resistant prostate cancer.

Findings from the phase 2 TheraP trial showed 177Lu-PSMA-617 to result in a higher prostate-specific antigen response rate vs with cabazitaxel in patients with metastatic castration-resistant prostate cancer.

At a live event discussing the case of a man, aged 75 years, with metastatic castration-resistant prostate cancer, Rana McKay, MD, focused on the makeup and results of the pivotal phase 4 CARD and phase 3 VISION studies.

David Morris, MD, FACS, discusses how PSMA PET imaging may impact targeted therapies for prostate cancer in the future.

During a presentation, Emmanuel S. Antonarakis, MD explained that homologous repair mutations and mismatch mutations in prostate cancer have therapeutic implications in the context of PARP inhibitors and PD-1 inhibitors.

According to Alicia Morgans, MD, MPH, there is a consistent differentiation and benefit when AR-targeted agent is added to the androgen deprivation therapy plus docetaxel backbone.

In an interview with Targeted Oncology, Ashley Ross, MD, PhD, discussed his recent advanced in prostate cancer, research around prostate cancer genomics, PET for staging and for identification of local disease, and more.

During a Targeted Oncology case-based event, Alan H. Bryce, MD, discussed decision-making for treating a patient with non-metastatic castration-resistant prostate cancer.

Results from a phase 3 study show that the continuous maintenance therapy of enzalutamide reduces the risk of disease progression in certain patients with metastatic castration resistant prostate cancer.

Chad Tang, MD, The University of Texas MD Anderson Cancer Center, discusses the design of the randomized, phase 2, basket EXTEND trial.

An abbreviated new drug application was approved by the FDA for leuprolide acetate injection as treatment of patients with advanced prostate cancer.

Adam Weiner, MD, discusses next steps for molecular testing in prostate cancer.

Following positive results and FDA action on pidnarulex in BRAC 1/2-positive ovarian cancer, a phase 1 study is exploring the agent in metastatic castration-resistant prostate cancer, in combination with talazoparib.

The phase 3 CHART study reveals better survival with rezvilutamide plus androgen deprivation therapy vs bicalutamide and androgen deprivation therapy in metastatic, hormone-sensitive prostate cancer.

Early results from the phase 1 JEWEL-101 study show XB002 is well-tolerated in patients with advanced solid tumors.

Mark Markowski, MD, PhD, discusses the results of a phase 1b/2 study examining treatment with sabizabulin in patients with metastatic castration-resistant prostate cancer.

Florida Cancer Specialists & Research Institute locations in Palm Beach County are now offering Pluvicto, the first targeted radioligand therapy approved by the FDA to treat an advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

Fred Saad, MD, FRSC, discusses the key biomarkers looked at in an analysis of the phase 3 PROpel trial analyzing olaparib plus abiraterone to treat patients with metastatic castration resistant prostate cancer.

Sheela Tejwani, MD, highlights some exciting recent trial data and shares clinical pearls for community oncologists treating mCSPC.

An expert oncologist describes her approaches to treating patients with castration-sensitive prostate cancer and low-volume metastatic disease.

An expert oncologist describes her approaches to treating patients with castration-sensitive prostate cancer and low-volume metastatic disease.

Dr Tejwani lists the frontline treatment options currently available for mCSPC and reviews the chosen treatment regimen in the presented patient case.

Sheela Tejwani, MD, presents the case of an 83-year-old man with mCSPC, and shares her first impressions as compared to her typical patients.

During a case-based roundtable event, Ashley Evan Ross, MD, PhD, reviewing therapeutic options for a patient with metastatic hormone-sensitive prostate cancer.